B

Bioretec Oy
OMXH:BRETEC

Watchlist Manager
Bioretec Oy
OMXH:BRETEC
Watchlist
Price: 0.16 EUR 0.63% Market Closed
Market Cap: €4.9m

Bioretec Oy
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Bioretec Oy
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
B
Bioretec Oy
OMXH:BRETEC
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Revenio Group Oyj
OMXH:REG1V
Other Items
-€1m
CAGR 3-Years
-85%
CAGR 5-Years
-83%
CAGR 10-Years
N/A
M
Modulight Oyj
OMXH:MODU
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Optomed Oyj
OMXH:OPTOMED
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
N
Nexstim Oyj
OMXH:NXTMH
Other Items
€13.3k
CAGR 3-Years
N/A
CAGR 5-Years
7%
CAGR 10-Years
N/A
B
Biohit Oyj
OMXH:BIOBV
Other Items
€1.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-18%
No Stocks Found

Bioretec Oy
Glance View

Market Cap
4.9m EUR
Industry
Health Care

Bioretec Ltd. develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. The company is headquartered in Tampere, Lansi-Suomen. The company went IPO on 2021-09-28. The firm operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oy’s existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Company’s products are used all over the world.

BRETEC Intrinsic Value
0.42 EUR
Undervaluation 62%
Intrinsic Value
Price
B

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett